Nontuberculous Mycobacteria in Guadeloupe, Martinique, and French Guiana from 1994 to 2012

Table 1

Isolation patterns of the two most frequently isolated NTM species, the M. avium complex and rapidly growing mycobacteria.

Parameters	Total	M. avium complex				Rapidly growing mycobacteria
		MAC	M. avium	M. intracellulare	Total MAC	M. abscessus	M. chelonae	M. fortuitum	RGM	Total RGMb,c,d
Years
1994–1998	158	39	23	1	62	7	1	35	5	49 ^b
1999–2003	166	15	25	3	43	12	1	41	4	60 b,c
2004–2008	182	34	23	15	72	10	7	38	2	58 ^d
2009–2012	145	4	16	32	52	8	6	39	3	56
	651	92	87	51	230	37	15	153	14	223
Age
≤19	18	2	0	1	3	3	1	3	1	8
20–39	122	27	38	6	71	6	0	16	0	22
40–54	166	24	26	15	65	7	3	35	4	50 ^b
55–69	125	5	11	17	33	8	3	38	2	52 ^c
≥70	130	8	5	10	23	10	7	41	6	65 ^d
N/A	90	26	7	2	35	3	1	20	1	26 ^b
Sex ratio	1.63	1.71	1.90	1.43	1.71	0.76	0.67	1.38	13.0	1.29
(M/F)	(380/233)	(48/28)	(55/29)	(30/21)	(𝟏𝟑𝟑/𝟕𝟖)	(16/21)	(6/9)	(83/60)	(13/1)	(𝟏𝟐𝟎/𝟗𝟑)
NA	—	16	3	—	19	—	—	10	—	10
HIV; (pos/neg)^a	129/96	43/4	40/8	5/5	𝟖𝟖/𝟏𝟕	0/10	1/5	15/32	1/2	𝟏𝟕/𝟒𝟗
Department
GLP	270	43	25	34	102	17	4	59	6	87 ^d
MTQ	194	19	32	10	61	13	10	56	3	84 b,c
GUF	187	30	30	7	67	7	1	38	5	52 ^b
Drug-susceptibility pattern^e; (nb tested)	—	D-CS, CLOFA, RBT, CLARIT; (𝑛, 74)	D-CS, CLOFA, CLARIT; (𝑛, 80)	RIF 15, D-CS, CLOFA, CLARIT; (𝑛, 46)	—	None	CLARIT; (𝑛, 15)	AMIK, OFLO 1.5, CIPRO 1.5, SPARFLO; (𝑛, 145)	OFLO 1.5, CIPRO 1.5, SPARFLO; (𝑛, 13)	—

aFor patients with known HIV serology; ^bM. flavescens isolate comprised; ^cM. aurum isolate comprised; ^dM. mucogenicum isolate comprised.
NA: not available; GLP: Guadeloupe; MTQ: Martinique; GUF: French Guiana.
eDrug-susceptibility pattern for a given NTM species was defined as ≤10% of all isolates displaying in vitro resistance [10]; AMIK: amikacin; CIPRO: ciprofloxacin; CLARIT: clarithromycin; CLOFA: clofazimine; D-CS: D-cycloserine; OFLO: ofloxacin; RBT: rifabutin; RIF: rifampin; SPARFLO: sparfloxacin. Note that drug concentration is mentioned for drugs screened at 2 different concentrations.